Intensity-modulated radiotherapy for lymphoma involving the mediastinum

被引:72
作者
Goodman, KA
Toner, S
Hunt, M
Wu, EJ
Yahalom, J
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 62卷 / 01期
关键词
IMRT; Hodgkin's lymphoma; conformal radiotherapy; mediastinal radiotherapy;
D O I
10.1016/j.ijrobp.2004.08.048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the feasibility, potential advantage, and indications for intensity-modulated radiotherapy (IMRT) in the treatment of Hodgkin's lymphoma or non-Hodgkin's lymphoma involving excessively large mediastinal disease volumes or requiring repeat RT. Methods and Materials: Sixteen patients with Hodgkin's lymphoma (n = 11) or non-Hodgkin's lymphoma (n 5) undergoing primary radiotherapy or repeat RT delivered via an IMRT plan were studied. The indications for using an IMRT plan were previous mediastinal RT (n = 5) or extremely large mediastinal treatment volumes (n = 11). For each patient, IMRT, conventional parallel-opposed (AP-PA), and three-dimensional conformal (3D-CRT) plans were designed using 6-MV X-rays to deliver doses ranging from 18 to 45 Gy (median, 36 Gy). The plans were compared with regard to dose-volume parameters. The IMRT/AP-PA and IMRT/3D-CRT ratios were calculated for each parameter. Results: For all patients, the mean lung dose was reduced using IMRT, on average, by 12% compared with AP-PA and 14% compared with 3D-CRT. The planning target volume coverage was also improved using IMRT compared with AP-PA but was not different from the planning target volume coverage obtained with 3D-CRT. Conclusion: In selected patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma involving the mediastinum, IMRT provides improved planning target volume coverage and reduces pulmonary toxicity parameters. It is feasible for RT of large treatment volumes and allows repeat RT of relapsed disease without exceeding cord tolerance. Additional follow-up is necessary to determine whether improvements in dose delivery affect long-term morbidity and disease control. (c) 2005 Elsevier Inc.
引用
收藏
页码:198 / 206
页数:9
相关论文
共 29 条
  • [1] Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease
    Bangerter, M
    Moog, F
    Buchmann, I
    Kotzerke, J
    Griesshammer, M
    Hafner, M
    Elsner, K
    Frickhofen, N
    Reske, SN
    Bergmann, L
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (10) : 1117 - 1122
  • [2] FITTING OF NORMAL TISSUE TOLERANCE DATA TO AN ANALYTIC-FUNCTION
    BURMAN, C
    KUTCHER, GJ
    EMAMI, B
    GOITEIN, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01): : 123 - 135
  • [3] CHOPRA R, 1993, BLOOD, V81, P1137
  • [4] Target coverage for head and neck cancers treated with IMRT: Review of clinical experiences
    Garden, AS
    Morrison, WH
    Rosenthal, DI
    Chao, KSC
    Ang, KK
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2004, 14 (02) : 103 - 109
  • [5] Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
    Hirsch, A
    VanderEls, N
    Straus, DJ
    Gomez, EG
    Leung, D
    Portlock, CS
    Yahalom, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1297 - 1305
  • [6] IMRT of large fields: Whole-abdomen irradiation
    Hong, L
    Alektiar, K
    Chui, C
    LoSasso, T
    Hunt, M
    Spirou, S
    Yang, J
    Amols, H
    Ling, C
    Fuks, Z
    Leibel, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (01): : 278 - 289
  • [7] EFFECT OF TREATMENT FOR HODGKINS-DISEASE ON PULMONARY-FUNCTION - RESULTS OF A PROSPECTIVE-STUDY
    HORNING, SJ
    ADHIKARI, A
    RIZK, N
    HOPPE, RT
    OLSHEN, RA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) : 297 - 305
  • [8] ANALYSIS OF CLINICAL COMPLICATION DATA FOR RADIATION HEPATITIS USING A PARALLEL ARCHITECTURE MODEL
    JACKSON, A
    TENHAKEN, RK
    ROBERTSON, JM
    KESSLER, ML
    KUTCHER, GJ
    LAWRENCE, TS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (04): : 883 - 891
  • [9] Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Kewalramani, T
    Zelenetz, AD
    Nimer, SD
    Portlock, C
    Straus, D
    Noy, A
    O'Connor, O
    Filippa, DA
    Teruya-Feldstein, J
    Gencarelli, A
    Qin, J
    Waxman, A
    Yahalom, J
    Moskowitz, CH
    [J]. BLOOD, 2004, 103 (10) : 3684 - 3688
  • [10] Kostakoglu L, 2002, J NUCL MED, V43, P1018